Purpose Febrile neutropenia (FNP) is a frequent complication of cancer care and evaluation often fails to identify a cause. [
Introduction
More than 50 % of patients with fever and neutropenia (febrile neutropenia, FNP) have established or occult infection which may be life-threatening [1] . Both bacterial and fungal organisms are frequently implicated as pathogens, but evaluation of the patient with FNP often fails to isolate a cause or site of the infection. Initiation of broad-spectrum antibiotics at the onset of FNP and rapid diagnosis and therapy for invasive fungal infections (IFI) both reduce mortality, but are associated with drug toxicities and high cost [2] [3] [4] [5] . Persistence of fever after 3-5 days of initial antibiotic treatment often necessitates additional laboratory and imaging investigations and sometimes escalation of antimicrobial therapy including empirical treatment with antifungal agents [1, 2] .
Diagnosis of infections in patients with FNP, in particular IFI, is hampered by the low positive and negative predictive values of available investigations [4] [5] [6] . Culture of blood, urine and other specimens has variable yield for many infections, and the targeted acquisition of tissue for culture (e.g. by biopsy) has risks. More recently antigen assays (e.g. β-1,3-glucan and galactomannan) and PCR techniques have been developed, but sensitivity and specificity remain less than perfect [5, 6] . Conventional radiography has very low sensitivity and CT may give transient findings which are nonspecific. An ideal diagnostic imaging tool for patients with FNP would identify infections at all body sites with high sensitivity and have an excellent negative predictive value, effectively excluding infection when the test was negative.
Because it localizes to metabolically active cells, 18 F-FDG is a useful tracer for imaging neoplastic conditions [7] . It is recognized that FDG is also taken up by neutrophils and activated macrophages associated with inflammatory, infectious or granulomatous processes [7, 8] . When FDG PET is performed on a hybrid PET/CT device, anatomical localization and characterization of focal areas of radiotracer accumulation may allow differentiation of malignancy from infection [7, 8] .
Preliminary studies and case series suggest that FDG PET/ CT may be a useful tool for diagnosis of infection in patients with malignancy [9] [10] [11] [12] [13] . FDG PET/CT is able to identify infections in patients with multiple myeloma, including some patients with severe neutropenia, lymphopenia or CD4 + lymphocytopenia [9] . FDG PET/CT may also detect infected central venous catheters, deep septic thrombophlebitis and IFI [10] [11] [12] [13] . In patients with IFI, FDG PET/CT appears at least as sensitive as conventional imaging techniques in identifying infections. Additionally, it may reveal previously unidentified foci of infection, and may have a role in monitoring response to antifungal therapy [12] [13] [14] . Whether FDG PET/ CT would be a useful addition to the routine investigations performed for persistent FNP is unknown.
The objective of this study was to evaluate the clinical impact of the addition of FDG PET/CT scanning in patients with FNP, when compared to conventional investigation and management. We prospectively evaluated the incremental value of FDG PET/CT scanning subsequent to conventional evaluation in 20 patients with persistent FNP at a cancer centre.
Materials and methods

Patients
The study was conducted at the Peter MacCallum Cancer Centre (Melbourne, Australia). This hospital is a tertiary referral centre for patients with a range of haematological and solid malignancies. As a pilot study, an arbitrarily designated cohort of 20 patients was planned for recruitment and prospective evaluation. The study was performed between May 2008 and September 2010. The target population consisted of hospitalized adult patients undergoing investigation and treatment for chemotherapy or diseaserelated FNP. Eligibility criteria included persisting fever (temperature≥38°C) and neutropenia (absolute neutrophil count <500 cells/μl) 5 days after onset of FNP, regardless of whether a potential cause of the fever had been identified. Patients were enrolled on day 5 of the febrile episode, with a view to undergoing FDG PET/CT within 3 days. Exclusion criteria were pregnancy, uncontrolled diabetes, concurrent administration of medication which would interfere with FDG uptake or PET image acquisition, or if FDG PET/CT scanning had already been scheduled as part of routine care.
Conventional evaluation
Conventional evaluation included daily complete clinical assessment of the patient and laboratory testing (blood and urine cultures, blood film, biochemistry and C-reactive protein). Additional microbiological investigations (such as sputum and wound swab cultures), serological tests, antigen capture assays, polymerase chain reaction assays and imaging were performed upon request of the treating clinician based on perceived clinical need. Imaging modalities available included conventional radiography, ultrasonography, CT, MRI and nuclear medicine scans. Invasive diagnostic procedures (including bronchoscopy and biopsy) were performed upon request of the treating clinician.
FDG PET/CT imaging protocol
All PET/CT studies were acquired on a Discovery STE PET/ CT scanner (GE Medical Systems, Milwaukee, WI). Patients fasted for a minimum of 4 h prior to scanning and generally in excess of 6 h. Blood glucose levels were <10 mmol/l at the time of FDG administration. A dose of 285-370 MBq was administered intravenously. A noncontrast CT scan was acquired in helical mode at 140 kVp and 80 mAs and reconstructed at a slice thickness of 3.27 mm. The FDG PET scan encompassed the same axial extent as the CT scan, from the skull base to the proximal thighs, representing four to six bed positions depending on the size of the patient. Each bed position had an acquisition time of 5 min and was acquired in 2-D or 3-D mode depending on the patient's weight, with 2-D imaging reserved for patients weighing >100 kg. The images were reconstructed using iterative reconstruction using the order-subset estimation maximization (OSEM) algorithm.
FDG PET/CT reporting
Each FDG PET/CT image was interpreted by a nuclear medicine physician who was provided with the results of the clinical evaluation, laboratory testing and conventional imaging (current at the time of scanning). The FDG PET/CT scan results were made available to the treating physicians immediately upon reporting. It was considered unethical to withhold diagnostic information in the context of a potentially life-threatening medical condition. As the study aim was to assess the incremental rather than independent diagnostic utility of FDG PET/CT compared to conventional techniques, there was no attempt at blinding of cases.
PET, CT and PET/CT fused images were reviewed on a dedicated workstation (Xeleris; GE Medical Systems). The FDG PET/CT images were interpreted qualitatively with the images normalized for hepatic uptake using a linear grey scale for the PET images and a rainbow colour scale for fused images set with an upper threshold standardized uptake value of approximately 7. On this scaling, hepatic activity, which typically has a standardized uptake value of around 3.5, is displayed in the middle of the colour range and represents approximately a transition from blue to green. On this colour scale, areas of enhanced FDG uptake are seen as yellow, orange or red. The FDG PET/CT images were reported as negative, equivocal or positive: negative was defined as no FDG uptake beyond normal physiological activity, equivocal as focal FDG uptake considered to be greater than expected physiological activity, but with uncertainty regarding the likely aetiology of this increased uptake based on pattern, intensity or correlative CT findings, and positive as FDG uptake beyond normal physiological activity suggestive of infection.
Comparison of FDG PET/CT with conventional evaluation
For each study participant, all conventional investigations were reviewed to determine the presence or absence of infection at the time of the FDG PET/CT scan. This assessment was performed independently by two infectious diseases physicians, at least one of whom was not involved with the patient's care. In the event of disagreement, adjudication was sought from a third infectious diseases physician.
The impact of the FDG PET/CT scan result on patient management was assessed using an adaptation of previously described tools for evaluating the impact of FDG PET/CT on infection and cancer management [9, 15] . The impact was deemed high if the FDG PET/CT result prompted additional investigations or procedures including referral for consultation, if it detected infections not identified by conventional evaluation or if it resulted in a change of antimicrobial management (prolongation, alteration or withholding of antimicrobial therapy that would otherwise have been initiated). Clinical impact was deemed low if the FDG PET/CT result only confirmed the results of the conventional evaluation and no other management alterations ensued, or if it failed to show infection identified by conventional evaluation.
Ethics review
The study was approved by the institutional human research ethics committee. Patients were required to provide written informed consent prior to participation.
Statistical analysis
Sensitivity of FDG PET/CT was defined as the number of infections identified by FDG PET/CT that had been identified by conventional evaluation prior to FDG PET/CT imaging. A 95 % confidence interval was calculated using the exact method with binomial distribution.
Results
Patient characteristics are presented in Table 1 . The results of the conventional evaluation, FDG PET/CT scanning and evaluation of FDG PET/CT scan impact are summarized in Table 2 . No adverse events related to FDG PET/CT scanning were reported.
Patient characteristics
A group of 20 neutropenic patients (13 men, 7 women) underwent FDG PET/CT scanning in addition to conventional evaluation after a minimum of 5 days of persistent FNP (Table 1) . Their median age was 61.5 years (range 28-70 years). The median duration of documented neutropenia prior to the onset of fever was 9 days (range 0-129 days). Of the 20 patients, 12 had a FDG PET/CT scan on days 5-7 of their febrile episode and 8 had a scan on day 8 or later due to logistic difficulties in accessing a scanning appointment.
Conventional evaluation
In 11 patients, 14 infections were diagnosed by conventional evaluation and were thought likely to have been present at the time of the FDG PET/CT scan ( Table 2) . Two of these infections were confirmed microbiologically: mixed enterobacteriaceae bloodstream infection thought to have arisen from an intraabdominal process ( Fig. 1) and Pseudomonas aeruginosa sternal osteomyelitis, which had been confirmed 4 months previously. Four patients (patients 2, 3, 5 and 8) had venous catheter-associated bloodstream infection prior to or at the onset of their febrile neutropenic episode. All had had the vascular catheter removed, and had directed antimicrobial therapy, conventional radiological exclusion of septic thrombophlebitis and repeat blood cultures. These infections were therefore deemed not to be present at the time of the FDG PET/CT scan and were considered not to be responsible for the persisting febrile episode.
FDG PET/CT scanning
The FDG PET/CT scan was positive in 16 patients, equivocal in 1 and negative in 3. The scan revealed 22 likely sites of infection (Table 2) . Patient 9 had an equivocal scan which revealed uptake beyond normal in the cardiac atria of pancreatitis, these infections were all confirmed by subsequent conventional evaluation including microbiological sampling, imaging and bronchoscopy.
Impact of FDG PET/CT scanning on patient management
The impact of the FDG PET/CT scan was considered 'high' in the management of 15 of the 20 patients (75 %; Table 2 ). The FDG PET/CT scan identified eight (subsequently confirmed) infections that were not previously diagnosed by conventional evaluation. The FDG PET/CT scan prompted the referral of three patients for surgical review and resulted in altered antimicrobial management in nine patients.
Discussion
This study supports the utility of FDG PET/CT scanning in severely neutropenic patients with persistent fever who are at high risk of infection. Importantly, the FDG PET/CT scan identified all deep tissue and organ infections identified by conventional evaluation and located an additional eight infections which conventional evaluation failed to identify. The FDG PET/CT scan had 'high' impact on patient management in 75 % of the studied cohort. The FDG PET/CT scan identified additional likely infections in nine patients, in eight of whom the infection was subsequently confirmed by further investigation. The FDG PET/CT scan prompted alteration of antimicrobial management in nine patients, including one patient who underwent prolonged therapy for liver abscess and one patient who was started on antifungal therapy. Notably, five patients (patients 2, 9, 12, 14 and 17) had empirical antifungal therapy withheld on day 5 of their FNP episode, this decision being supported by the FDG PET/CT scan which suggested the absence of IFI. These patients all recovered and did not manifest evidence of IFI following the scan. In the five patients whose FDG PET/CT scan had 'low' impact upon management, two had no cause of the FNP identified by either FDG PET/CT or The limitations of the study include the small number of patients, enrolment from a single institution and the fact that allogeneic bone marrow transplant recipients were not included. FDG PET/CT is more readily available at our centre than at many other centres treating cancer patients and our centre's reporting nuclear medicine physicians have considerable expertise in the use of FDG PET/CT for the diagnosis of infection. The delay experienced by some patients in awaiting a scan (beyond day 5-7 of the febrile episode) may have reduced the sensitivity of FDG PET/CT for detection of infection. The presence of neutropenia appears not to compromise the sensitivity of this technique and has an advantage over conventional nuclear medicine infection scanning, where the requirement for radiolabelling of white blood cells may not be met in the setting of low circulating numbers of leucocytes [16] . Radiolabelled anti-granulocyte monoclonal antibodies, or their fragments, have been used to image infectious diseases [17] . The resolution of FDG PET/CT is generally higher than that of images obtained with anti-granulocyte monoclonal antibodies, which is often the case in monoclonal antibody type studies. Moreover, antigranulocyte monoclonal antibodies are not able to reliably differentiate inflammation from infection, and are therefore not necessarily more specific than FDG PET/CT [17] . To our knowledge, there is no reported use of radiolabelled antigranulocyte monoclonal antibodies in the assessment of FNP.
Our study adds further support to the usefulness of FDG PET/CT in severely neutropenic patients [9, 13] . In contrast to the study by Mahfouz et al. [9] , in which the majority of patients were scanned for staging their malignancy and a small proportion were severely immunocompromised (neutropenic, lymphopenic or CD4 + lymphocytopenic), our patients with severe persistent neutropenia were all scanned to identify new or already documented infections. While most patients in both studies had one or more infections identified (including previously unidentified and silent infections), the FDG PET/CT scan affected management in a higher proportion of patients in the current study (75 % vs. 48 % of patients). FDG PET/CT has previously been used for monitoring response to therapy and for helping to establish when discontinuation of therapy is appropriate, in the setting of bacterial and fungal infections [8, 12, 13, 15] . When FDG PET/CT identifies infection in a patient with persistent FNP, follow-up scanning has theoretical merit for monitoring response to treatment, and for excluding other new clinically unsuspected sites of infection, although this was not evaluated as a part of the current study. In light of the findings from this pilot study, the current role of FDG PET/CT is perhaps as an adjunct in persistently febrile patients (for more than 5 days) to identify or exclude occult infection missed in their conventional diagnostic work-up. A negative FDG PET/CT test may support a clinical decision to withhold empirical antifungal therapy in this situation. Use of FDG PET/CT as an up-front test (i.e. in the first 1-3 days of FNP) to direct further imaging or sampling tests may be worth evaluating.
In conclusion, FDG PET/CT is a useful investigation modality in patients with severe neutropenia and fever present for 5 days, and is capable of detecting deep tissue and organ infections identified by conventional evaluation. Additional sites of infection may be identified and significant management alterations result following the use of FDG PET/CT scanning in this population. A negative FDG PET/CT scan may provide greater confidence in a decision to withhold empirical antifungal therapy. Larger multicentre evaluations of the contribution of this technique to the management of FNP in patients with a broad range of underlying malignancies, the optimal timing of FDG PET/ CT scanning for diagnostic yield, and the cost-benefit of this investigation are required.
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